The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration of process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing, and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platforms.
In this webinar, you will learn:
David Loong, Ph.D.
Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
David Loong is our senior consultant, novel modalities APAC, bioprocessing strategy. Previously, David held roles as a senior scientist in biotech startups encompassing cell & gene therapy process development services, mAb discovery, and preclinical development. He has an extensive track record providing contract research services as a senior research scientist at AMRI Global, and as a product custodian for API GMP manufacturing at GSK. He holds a Ph.D. in synthetic organic chemistry from the Australian National University and a BTech(Hons) from Massey University (NZ) specializing in chemistry and process engineering.
Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng is our senior consultant responsible for core modalities APAC bioprocessing strategy, where she looks closely into customer and market insights in the vaccine industry and supports strategy development, and customer collaborations. With more than 13 years of pharmaceutical industry experience, she has held various regional roles in the technical and marketing field and drove business development in the plasma and vaccine fields. Josephine holds a B.S. and an M.S. in bio-resources & agriculture from National Taiwan University with a focus on protein expression, purification, and mAbs preparation.